Description
Anti-PIVKA-II Antibody, Non-Fucosylated (BioBet-1601ZP) is a human monoclonal IgG antibody against PIVKA-II. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Hepatocellular Carcinoma (HCC); Liver Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PIVKA-II antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
protein induced by vitamin K absence/antagonist-II
Background
Des-gamma carboxyprothrombin (DCP), also known as protein induced by vitamin K absence/antagonist-II (PIVKA-II), is an abnormal form of the coagulation protein, prothrombin. Normally, the prothrombin precursor undergoes post-translational carboxylation (addition of a carboxylic acid group) by gamma-glutamyl carboxylase in the liver prior to secretion into plasma. DCP/PIVKA-II may be detected in people with deficiency of vitamin K (due to poor nutrition or malabsorption) and in those taking warfarin or other medication that inhibits the action of vitamin K.
Alternative Names
PIVKA-II; protein induced by vitamin K absence/antagonist-II; Des-gamma carboxyprothrombin; DCP
Cellular Localization
Nucleus
Involvement in Disease
Diseases associated with DCPS include Al-Raqad Syndrome and Autosomal Recessive Non-Syndromic Intellectual Disability.
Related Pathways
Its related pathways are Gene Expression and Deadenylation-dependent mRNA decay.
Function
The peeling and removing enzyme catalyzes the cleavage of the remaining cap structure after the mRNA decay pathway mediated by 3'->5' exosomes degrades the mRNA. It can hydrolyze the cap structure of up to 10 nucleotide substrates (small cap oligonucleotides), such as 7-methylguanosine triphosphate (m7GpppG), and specifically release 5'phosphorylated RNA Fragment and 7-methylguanosine monophosphate (m7GMP). The cleavage cap mimics the structure, such as trimethylguanosine nucleoside triphosphate (m3(2,2,7)GpppG), which is very inefficient. It cannot hydrolyze unmethylated cap mimics (GpppG), and has no shelling activity on complete m7GpppG-capped mRNA molecules greater than 25 nucleotides in length. Can not hydrolyze 7-methylguanosine diphosphate (m7GDP) into m7GMP. It may also participate in the 5'->3 mRNA decay pathway; the downstream product m7GDP released by the uncoating activity mediated by 5'->3' mRNA may also be converted into m7GMP by DCPS. It binds to m7GpppG and strongly binds to m7GDP. It plays a role in the first intron splicing of pre-mRNAs. Inhibition of activity-induced cell death.
Post-translational modifications
1.Ubiquitination at Lys128 and Lys138 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-1601ZP
Description
It relates to antibody or binding proteins which bind to PIVKA II, and may be used, for example, in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.
Antibody Indication
Hepatocellular Carcinoma (HCC); Liver Cancer
